EQT posts record $20 bln Galderma gain; Q1 fee-generating assets remain flat

EQT reported approximately €20 billion in capital gains from the Galderma sale, calling it the largest fully monetized capital gain from a single fund in private equity history. Fee-generating assets under management were flat at €142 billion and total assets under management slipped to €269 billion from €273 billion, while BPEA IX closed at $15.6 billion and evergreen vehicles posted a record €1 billion of net inflows. The quarter also included €34 million of share repurchases and a launched AI infrastructure strategy, offsetting otherwise steady underlying fund valuations.

Analysis

This is a signaling event for the private-markets complex, not just a one-off realization. A large, clean monetization at scale validates continuation-value marks across the franchise and should compress the perceived “liquidity discount” on evergreen and secondaries platforms, especially if LPs start assuming more frequent realizations rather than paper gains. The second-order effect is that fundraising power likely improves just as public-market volatility makes sponsor exits harder, which can widen the moat for firms with both capital formation and distribution capabilities.

The bigger strategic tell is that capital recycling is becoming the main growth engine: realized gains and sponsor-backed block execution create fresh dry powder and reduce dependence on multiple expansion. That matters for competitors because firms without top-tier exit access may be forced to hold longer, which drags fee growth and can pressure valuations in the next 2-3 quarters if marks stay flat while fundraising slows. Coller integration is the real medium-term catalyst: if the platform can quickly cross-sell and scale the acquired fee base, the market may re-rate the stock on higher durable fee-bearing AUM rather than volatile performance fees.

The contrarian risk is that investors may overestimate how repeatable a “hero exit” is. One marquee monetization does not eliminate the structural headwind of lower public multiples; if that persists, transaction cadence and carry realization could normalize down after a strong quarter. In that setup, the near-term upside is more about multiple re-rating on perceived execution quality than about immediate earnings acceleration, so the stock can stall even while fundamentals remain solid.

Key Decisions for Investors

• Buy EQTAB on pullbacks over the next 1-2 weeks; target a 6-12 month re-rating as the market prices in higher-quality fee growth and Coller-related upside. Risk/reward improves if the stock remains anchored to flat quarterly marks.
• Sell downside puts on EQTAB with 3-6 month tenor to harvest elevated implied volatility around integration and exit-timing uncertainty. Best if you want exposure to long-term AUM compounding without paying full upside optionality.
• Pair long EQTAB vs short a listed PE manager with weaker fundraising/realization visibility over 3-6 months. The trade benefits from a widening gap between platforms that can monetize assets and those reliant on paper performance.
• If you already own EQTAB, trim after any sharp post-print rally and hold the core into the Coller close window in 2026. The market may over-anticipate synergy capture before regulatory timing becomes clearer.
• Watch for weakness in public-exit-sensitive private markets names if sponsor-backed blocks slow; that would validate a short basket against firms with slower liquidity conversion. Reassess if broad multiple expansion returns to the listed markets.